Distributing since 1889 • Employee Owned for Better Service
Your 1st Choice!
Sign In
Quick Search:

Shopping Cart Cart |  My Account |  View Printable Page Print
Product Detail

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Plitnick, Lisa M. PhD
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics Cover Image
Pricing & Availability
Available: 0
List Price:$174.95

Email this title to a friend Email this title to a friend
Printer friendly version Printer friendly version

Other formats:
Book Information
Edition: 1st
Publisher: Academic Press, Incorporated
ISBN: 0-12-394810-X (012394810X)
ISBN-13: 978-0-12-394810-6 (9780123948106)
New Edition: 0-443-13344-1
Binding: Hardcover
Copyright: 2013
Publish Date: 07/13
Weight: 2.42 Lbs.
Pages: 416
Carton Quantity: 16
Subject Class: PHM (Pharmacy and Pharmaceutical Industry)
Remarks:
A New Edition of this title is due 08/24
Return Policy: Returns accepted up to 90 days provided no other recalls or return restrictions apply.
Table Of Contents: View
Contributing Authors: View
 
Class Specifications
Discipline: Pharmacology
Subject Definition: Biopharmaceutics; Models, Chemical; Pharmacokinetics
NLM Class: QV 38
LC Class: RM301.4
Abstract: Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. Covers early de-risking strategies and designs of safety assessment programs for novel biopharmaceuticals and vaccines, as well as follow-on biologics or "biosimilars". A multi-authored book with chapters written by qualified experts in their respective fields.

Follow Matthews Book Co. on:
Follow Matthews Book Co. on Twitter

Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews Privacy Statement